1. Abé C, Liberg B, Song J, Bergen SE, Petrovic P, Ekman CJ et al.Longitudinal Cortical Thickness Changes in Bipolar Disorder and the Relationship to Genetic Risk, Mania, and Lithium Use. Biological Psychiatry 2019; S0006322319316270.
2.
Benedetti F, Serretti A, Pontiggia A, Bernasconi A, Lorenzi C, Colombo C et al. Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-β −50 T/C SNP. Neuroscience Letters 2005; 376: 51–55.
3.
Bremer T, Diamond C, McKinney R, Shehktman T, Bar rett TB, Herold C et al. The Pharmacogenetics of Lithium Response Depends upon Clinical Co-Morbidity. Mol Diag Ther 2007; 11: 161–170.
4.
Budde M, Degner D, Brockmöller J, Schulze TG. Pharmaco genomic aspects of bipolar disorder: An update. European Neuropsychopharmacology 2017; 27: 599–609.
5.
Bush WS, Moore JH. Chapter 11: Genome-wide association studies. PLoS Comput Biol 2012; 8:e1002822.
6.
Campos-de-Sousa S, Guindalini C, Tondo L, Munro J, Osbor ne S, Floris G et al. Nuclear Receptor Rev-Erb- α Circadian Gene Variants and Lithium Carbonate Prophylaxis in Bipolar Affective Disorder. J Biol Rhythms 2010; 25: 132–137.
7.
Chen C-H, Lee C-S, Lee M-TM, Ouyang W-C, Chen C-C, Chong M-Y et al. Variant GADL1 and response to lithium therapy in bipolar I disorder. N Engl J Med 2014; 370: 119–128.
8.
Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 2013; 346: f3646–f3646.
9.
Coutts F, Palmos AB, Duarte RRR, de Jong S, Lewis CM, Dima D et al. The polygenic nature of telomere length and the an ti-ageing properties of lithium. Neuropsychopharmacology 2019; 44: 757–765.
10.
Dmitrzak-Weglarz M, Rybakowski JK, Slopien A, Czerski PM, Leszczynska-Rodziewicz A, Kapelski P et al. Dopamine receptor D1 gene -48A/G polymorphism is associated with bipolar illness but not with schizophrenia in a Polish popu lation. Neuropsychobiology 2006; 53: 46–50.
11.
Dmitrzak-Weglarz M, Rybakowski JK, Suwalska A, Skibin ska M, Leszczynska-Rodziewicz A, Szczepankiewicz A et al.Association studies of the BDNF and the NTRK2 gene poly morphisms with prophylactic lithium response in bipolar patients. Pharmacogenomics 2008; 9: 1595–1603.
12.
Dome P, Rihmer Z, Gonda X. Suicide Risk in Bipolar Disorder: A Brief Review. Medicina (Kaunas) 2019; 55. DOI: 10.3390/medicina55080403.
13.
Dudbridge F, Gusnanto A. Estimation of significance thre sholds for genomewide association scans. Genet Epidemiol 2008; 32: 227–234.
14.
eQTLGen Consortium, BIOS Consortium, the Bipolar Disor der Working Group of the Psychiatric Genomics Consortium, Stahl EA, Breen G, Forstner AJ et al. Genome-wide association study identifies 30 loci associated with bipolar disorder. Nat Genet 2019; 51: 793–803.
15.
Fabbri C, Serretti A. Clinical application of antidepressant pharmacogenetics: Considerations for the design of future studies. Neuroscience Letters 2018; 133651.
16.
Geoffroy PA, Etain B, Lajnef M, Zerdazi E-H, Brichant-Pe titjean C, Heilbronner U et al. Circadian genes and lithium response in bipolar disorders: associations with PPARGC1A (PGC-1 α ) and RORA: Circadian genes and lithium response. Genes, Brain and Behavior 2016; 15: 660–668.
17.
Grof P. Excellent lithium responders: people whose lives have been changed by lithium prophylaxis. W: Lithium: 50 Years of Psychopharmacology. Birch NJ, Gallicchio VS, Becker RW (red.): Weidner Publishing Group, Cheshire 1999, 365–1.
18.
Grof P. Sixty Years of Lithium Responders. NPS 2010; 62: 8–16.
19.
Grof P, Duffy A, Alda M, Hajek T. Lithium response across generations. Acta Psychiatr Scand 2009; 120: 378–385.
20.
Grof P, Duffy A, Cavazzoni P, Grof E, Garnham J, MacDougall M et al. Is response to prophylactic lithium a familial trait? J Clin Psychiatry 2002a; 63: 942–947.
21.
Grof P, Duffy A, Cavazzoni P, Grof E, Garnham J, MacDougall M et al. Is response to prophylactic lithium a familial trait? J Clin Psychiatry 2002b; 63: 942–947.
22.
Hauser J, Leszczyńska-Rodziewicz A. Farmakogenetyka leków przeciwpsychotycznych. Psychiatria 2004; 1: 81–89.
23.
Hauser J, Leszczyńska-Rodziewicz A, Skibińska M. Wspólne podłoże genetyczne schizofrenii i choroby afektywnej dwu biegunowej? Psychiatria 2005; 2: 145–153.
24.
Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, Collins FS et al. Potential etiologic and functional impli cations of genome-wide association loci for human diseases and traits. Proceedings of the National Academy of Sciences 2009; 106: 9362–9367.
25.
Hou L, Heilbronner U, Degenhardt F, Adli M, Akiyama K, Akula N et al. Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet 2016; 387: 1085–1093.
26.
Huser V, Sincan M, Cimino JJ. Developing genomic knowledge bases and databases to support clinical management: current perspectives. Pharmgenomics Pers Med 2014; 7: 275–283.
27.
Hyman S. Mental health: Depression needs large human genetics studies. Nature 2014; 515: 189–191.
28.
International Consortium on Lithium Genetics (ConLi+-Gen), Amare AT, Schubert KO, Hou L, Clark SR, Papiol S, et al. Association of Polygenic Score for Schizophrenia and HLA Antigen and Inflammation Genes With Response to Lithium in Bipolar Affective Disorder: A Genome-Wide Association Study. JAMA Psychiatry 2018; 75: 65–74.
29.
Ioannidis JPA, Thomas G, Daly MJ. Validating, augmenting and refining genome-wide association signals. Nat Rev Genet 2009; 10: 318–329.
30.
Jacobs A, Hagin M, Shugol M, Shomron N, Pillarad N, Fañanáse L et al. The black sheep of the family- whole-exome sequencing in family of lithium response discordant bipolar monozygotic twins. European Neuropsychopharmacology 2020; 34: 19–27.
31.
Kleindienst N, Engel R, Greil W. Which clinical factors pre dict response to prophylactic lithium? A systematic review for bipolar disorders. Bipolar Disorders 2005; 7: 404–417.
32.
Kliwicki S, Chłopocka-Woźniak M, Rudnicka E, Rybakow ski JK et al. Skuteczność długoterminowego stosowania litu w chorobie afektywnej dwubiegunowej. Farmakoterapia w Psychiatrii i Neurologii, 2014; 1: 5–13.
33.
Krebs CE, Ori APS, Vreeker A, Wu T, Cantor RM, Boks MPM et al. Whole blood transcriptome analysis in bipolar disorder reveals strong lithium effect. Psychol Med 2019; 1–12.
34.
Malhotra AK. Association Between Common Variants Near the Melanocortin 4 Receptor Gene and Severe Antipsychotic Drug–Induced Weight Gain. Arch Gen Psychiatry 2012; 69: 904.
35.
Malhotra D, Sebat J. CNVs: Harbingers of a Rare Variant Revolution in Psychiatric Genetics. Cell 2012; 148: 1223–1241.
36.
Mamdani F, Alda M, Grof P, Young LT, Rouleau G, Turecki G. Lithium Response and Genetic Variation in the CREB Family of Genes. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 500–504.
37.
Manchia M, Adli M, Akula N, Ardau R, Aubry J-M, Backlund L et al. Assessment of Response to Lithium Maintenance Treatment in Bipolar Disorder: A Consortium on Lithium Genetics (ConLiGen) Report. PLoS ONE 2013; 8:e65636.
38.
Manchia M, Congiu D, Squassina A, Lampus S, Ardau R, Chil lotti C et al. No association between lithium full responders and the DRD1, DRD2, DRD3, DAT1, 5-HTTLPR and HTR2A genes in a Sardinian sample. Psychiatry Research 2009; 169: 164–166.
39.
Masui T, Hashimoto R, Kusumi I, Suzuki K, Tanaka T, Naka gawa S et al. A possible association between the −116C/G sin gle nucleotide polymorphism of the XBP1 gene and lithiumprophylaxis in bipolar disorder. Int J Neuropsychopharmacol 2006a; 9: 83–88.
40.
Masui T, Hashimoto R, Kusumi I, Suzuki K, Tanaka T, Naka gawa S, et al. Lithium response and Val66Met polymorphism of the brain-derived neurotrophic factor gene in Japanese patients with bipolar disorder. Psychiatric Genetics 2006b; 16: 49–50.
41.
Masui T, Hashimoto R, Kusumi I, Suzuki K, Tanaka T, Naka gawa S et al. A possible association between missense poly morphism of the breakpoint cluster region gene and lithium prophylaxis in bipolar disorder. Progress in Neuro-Psycho pharmacology and Biological Psychiatry 2008; 32: 204–208.
42.
McCarthy MJ, Nievergelt CM, Shekhtman T, Kripke DF, Wel sh DK, Kelsoe JR. Functional genetic variation in the Rev-Erb α pathway and lithium response in the treatment of bipolar disorder. Genes, Brain and Behavior 2011; 10: 852–861.
43.
Michelon L, Meira-Lima I, Cordeiro Q, Miguita K, Breen G, Collier D et al. Association study of the INPP1, 5HTT, BDNF, AP-2β and GSK-3β GENE variants and restrospectively sco red response to lithium prophylaxis in bipolar disorder. Neuroscience Letters 2006; 403: 288–293.
44.
O’Connell RA, Mayo JA, Flatow L, Cuthbertson B, O’Brien BE. Outcome of Bipolar Disorder on Long-Term Treatment with Lithium. The British Journal of Psychiatry 1991; 159: 123–129.
45.
Perlis RH, Smoller JW, Ferreira MAR, McQuillin A, Bass N, Lawrence J et al. A Genomewide Association Study of Re sponse to Lithium for Prevention of Recurrence in Bipolar Disorder. AJP 2009; 166: 718–725.
46.
Pirmohamed M. Pharmacogenetics and pharmacogenomics: Editorial. British Journal of Clinical Pharmacology 2001; 52: 345–347.
47.
Rybakowski JK: Genetic Influences on Response to Mood Stabilizers in Bipolar Disorder. CNS Drugs 2013; 27: 165–173.
48.
Rybakowski JK. Lit – niezwykły lek w psychiatrii. Termedia Wydawnictwa Medyczne, Poznań 2019.
49.
Rybakowski JK. Leczenie zespołów maniakalnych i hipo maniakalnych. W: Standardy leczenia farmakologicznego niektórych zaburzeń psychicznych. Jarema M. (red.), Via Medica, Gdańsk 2015; 92–97.
50.
Rybakowski JK. Oblicza choroby maniakalno-depresyjnej. Termedia Wydawnictwo Medyczne, Poznań 2018; 65–75.
51.
Rybakowski JK. Two generations of mood stabilizers. The International Journal of Neuropsychopharmacology 2007; 10: 709–711.
52.
Rybakowski JK, Dmitrzak-Weglarz M, Kliwicki S, Hauser J. Polymorphism of circadian clock genes and prophylactic lithium response. Bipolar Disord 2014; 16: 151–158.
53.
Rybakowski JK, Dmitrzak-Weglarz M, Suwalska A, Lesz czynska-Rodziewicz A, Hauser J. Dopamine D1 receptor gene polymorphism is associated with prophylactic lithium respon se in bipolar disorder. Pharmacopsychiatry 2009; 42: 20–22.
54.
Rybakowski JK, Suwalska A, Czerski PM, Dmitrzak-Weglarz M, Leszczynska-Rodziewicz A, Hauser J. Prophylactic ef fect of lithium in bipolar affective illness may be related to serotonin transporter genotype. Pharmacol Rep 2005a; 57: 124–127.
55.
Rybakowski JK, Suwalska A, Skibinska M, Szczepankiewicz A, Leszczynska-Rodziewicz A, Permoda A et al. Prophylactic Lithium Response and Polymorphism of the Brain-Derived Neurotrophic Factor Gene. Pharmacopsychiatry 2005b; 38: 166–170.
56.
Scherer SW, Lee C, Birney E, Altshuler DM, Eichler EE, Carter NP et al. Challenges and standards in integrating surveys of structural variation. Nat Genet 2007; 39: S7–S15.
57.
Schizophrenia Working Group of the Psychiatric Genomics Consortium, Bipolar Disorder Working Group of the Psychia tric Genomics Consortium, Cross-Disorder Working Group of the Psychiatric Genomics Consortium, Ruderfer DM, Fa nous AH, Ripke S et al. Polygenic dissection of diagnosis and clinical dimensions of bipolar disorder and schizophrenia. Mol Psychiatry 2014; 19: 1017–1024.
58.
Schulze TG, Alda M, Adli M, Akula N, Ardau R, Bui ET et al.The International Consortium on Lithium Genetics (Con LiGen): An Initiative by the NIMH and IGSLI to Study the Genetic Basis of Response to Lithium Treatment. Neuropsy chobiology 2010; 62: 72–78.
59.
Serretti A, Lilli R, Mandelli L, Lorenzi C, Smeraldi E. Seroto nin transporter gene associated with lithium prophylaxis in mood disorders. Pharmacogenomics J 2001; 1: 71–77.
60.
Serretti A, Malitas PN, Mandelli L, Lorenzi C, Ploia C, Ale vizos B et al. Further evidence for a possible association between serotonin transporter gene and lithium prophy laxis in mood disorders. Pharmacogenomics J 2004; 4: 267–273.
61.
Silberberg G, Levit A, Collier D, St. Clair D, Munro J, Kerwin RW et al. Stargazin involvement with bipolar disorder and response to lithium treatment. Pharmacogenetics and Ge nomics 2008; 18: 403.
62.
Song J, Bergen SE, Di Florio A, Karlsson R, Charney A, Ru derfer DM et al. Genome-wide association study identifies SESTD1 as a novel risk gene for lithium-responsive bipolar disorder. Mol Psychiatry 2016; 21: 1290–1297.
63.
Squassina A, Manchia M, Borg J, Congiu D, Costa M, Geo rgitsi M et al. Evidence for association of an ACCN1 gene variant with response to lithium treatment in Sardinian patients with bipolar disorder. Pharmacogenomics 2011; 12: 1559–1569.
64.
Stern S, Linker S, Vadodaria KC, Marchetto MC, Gage FH. Prediction of response to drug therapy in psychiatric disor ders. Open Biol 2018; 8. DOI: 10.1098/rsob.180031.
65.
Suga Y, Yoshimoto K, Numata S, Shimodera S, Takamura S, Kamimura N et al. Structural variation in the glycogen synthase kinase 3β and brain‐derived neurotrophic factor genes in Japanese patients with bipolar disorders. Neuropsy chopharmacol Rep 2019; npr2.12083.
66.
Szczepankiewicz A, Rybakowski JK, Suwalska A, Skibinska M, Leszczynska-Rodziewicz A, Dmitrzak-Weglarz M et al.Association study of the glycogen synthase kinase-3β gene polymorphism with prophylactic lithium response in bipolar patients. The World Journal of Biological Psychiatry 2006; 7: 158–161.
67.
Szczepankiewicz A, Skibinska M, Suwalska A, Hauser J, Rybakowski JK. The association study of three FYN poly morphisms with prophylactic lithium response in bipolar patients. Human Psychopharmacology: Clinical and Expe rimental 2009; 24: 287–291.
68.
Tennessen JA, Bigham AW, O’Connor TD, Fu W, Kenny EE, Gravel S et al. Evolution and Functional Impact of Rare Co ding Variation from Deep Sequencing of Human Exomes. Science 2012; 337: 64–69.
69.
The International Schizophrenia Consortium. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009; 460:7 48–752.
70.
Trevor Young L, Cooke RG, Robb JC, Levitt AJ, Joffe RT. Anxio us and non-anxious bipolar disorder. Journal of Affective Disorders 1993; 29: 49–52.
71.
Vogel F. Moderne Probleme der Humangenetik; in: Heilmey er L, Schoen R, de Rudder B (eds): Ergebnisse der InnerenMedizin und Kinderheilkunde. Berlin, Heidelberg, Springer, 1959, pp 52–125.
72.
Wang Z, Fan J, Gao K, Li Z, Yi Z, Wang L et al. Neurotrophic Tyrosine Kinase Receptor Type 2 (NTRK2) Gene Associated with Treatment Response to Mood Stabilizers in Patients with Bipolar I Disorder. J Mol Neurosci 2013; 50: 305–310.
73.
Washizuka S, Ikeda A, Kato N, Kato T. Possible relationship between mitochondrial DNA polymorphisms and lithium response in bipolar disorder. Int J Neuropsychopharmacol 2003; 6: 421–424.
74.
Weickert CS, Weickert TW, Pillai A, Buckley PF. Biomarkers in Schizophrenia: A Brief Conceptual Consideration. Disease Markers 2013; 35: 3–9.
75.
Willour VL, Seifuddin F, Mahon PB, Jancic D, Pirooznia M, Steele J et al. A genome-wide association study of attempted suicide. Molecular Psychiatry 2012; 17: 433–444.
76.
Wu T-N, Chen C-K, Lee C-S, Wu B-J, Sun H-J, Chang C-H et al. Lithium and GADL1 regulate glycogen synthase kinase-3 activity to modulate KCTD12 expression. Sci Rep 2019; 9: 10255.
